After finishing at $7.31 in the prior trading day, Enovix Corporation (NASDAQ: ENVX) closed at $6.70, down -8.34%. On the day, 4818954 shares were traded.
Ratios:
Our goal is to gain a better understanding of ENVX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.15 and its Current Ratio is at 5.30. In the meantime, Its Debt-to-Equity ratio is 0.74 whereas as Long-Term Debt/Eq ratio is at 0.72.
On July 21, 2023, TD Cowen Downgraded its rating to Market Perform which previously was Outperform and also upped its target price recommendation from $19 to $20.
On January 11, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $20.Canaccord Genuity initiated its Buy rating on January 11, 2023, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 24 ’23 when Talluri Rajendra K bought 1,434 shares for $13.94 per share. The transaction valued at 19,990 led to the insider holds 2,018,901 shares of the business.
ATKINS BETSY S sold 36,000 shares of ENVX for $585,000 on Aug 11 ’23. The Director now owns 159,369 shares after completing the transaction at $16.25 per share. On Jun 20 ’23, another insider, ATKINS BETSY S, who serves as the Director of the company, sold 4,528 shares for $15.02 each. As a result, the insider received 68,011 and left with 195,369 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 147.77 while its Price-to-Book (P/B) ratio in mrq is 4.34.
Stock Price History:
Over the past 52 weeks, ENVX has reached a high of $23.90, while it has fallen to a 52-week low of $7.05.
Shares Statistics:
A total of 167.39M shares are outstanding, with a floating share count of 138.19M. Insiders hold about 17.99% of the company’s shares, while institutions hold 50.89% stake in the company.
Earnings Estimates
Its stock is currently analyzed by Enovix Corporation different market analysts. The consensus estimate for the next quarter is $2.52, with high estimates of $0.92 and low estimates of $56.54.
Analysts are recommending an EPS of between $Healthcare and $Technology for the fiscal current year, implying an average EPS of $Healthcare.
